Citius Pharmaceuticals Inc
NASDAQ:CTXR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (0.7), the stock would be worth $8.23 (1 283% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.1 | $0.6 |
0%
|
| 3-Year Average | 0.7 | $8.23 |
+1 283%
|
| 5-Year Average | 40.9 | $448.44 |
+75 255%
|
| Industry Average | 2.7 | $29.95 |
+4 933%
|
| Country Average | 1.5 | $16.33 |
+2 645%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Citius Pharmaceuticals Inc
NASDAQ:CTXR
|
13.3m USD | 0.1 | -0.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 9.2 | 43 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 3.5 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 2.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 3.7 | 28 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 2.6 | 15 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 2.9 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 56 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 2.6 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 1.1 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 2 | 17.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.9 |
| Median | 1.5 |
| 70th Percentile | 2.9 |
| Max | 566 432.7 |
Other Multiples
Citius Pharmaceuticals Inc
Glance View
Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. The company is headquartered in Cranford, New Jersey and currently employs 15 full-time employees. The company went IPO on 2017-08-03. The firm develops and commercializes critical care products with a focus on anti-infective products in adjunct cancer care, prescription products and mesenchymal stem cell therapy. The company has five products: Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. Halo-Lido is a corticosteroid-lidocaine topical formulation, which is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. NoveCite is a mesenchymal stem cell therapy for the treatment of ARDS. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma.
